INTELLIGENT BIO SOLUTIONS INC (INBS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.23-3.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · INBS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -83.2% |
| Our one-year growth estimate | diamond | 50.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 133.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
INBS — private placement
Dated 2026-09-02
Entry into a Material Definitive Agreement. On August 31, 2026, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor for the sale by the Company of (i) 2,036,659 shares (the “Shares”) of the Company’s common stock (or Series M Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series N-1 warrants to purchase up to an aggrega…
Why it matters: Successful precision testing helps the FDA submission and lowers regulatory risk for U.S. entry.
Supportive ifPrecision testing shows consistent results in all required tests and is part of the FDA submission.
Worry ifPrecision testing does not show steady results. It has a lot of changes.
Why it matters: Earnings results will provide insights into revenue and cash flow trends.
Watch forEarnings report shows revenue growth and improved cash flow.
Also watch forEarnings report shows declining revenue and worsening cash flow.
Why it matters: Positive cash flow from operations is key for survival. It shows good cash management.
Supportive ifOperating cash flow reported at $0 or above in Q3.
Worry ifOperating cash flow was worse than -$4.33 million. This shows ongoing cash issues.
Why it matters: Sector growth impacts company performance. A rebound could boost investor confidence and stock performance.
Watch forSector revenue growth speeds up to over 9% year-over-year.
Also watch forSector revenue growth slows down to below 9% year-over-year.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$294 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $1,075 loss on $10,000 · 10.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,176 loss on $10,000 · 91.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More active customers show strong demand in the market. This is important for steady revenue growth.
Supportive ifActive customer count increases beyond 502 in the next quarter.
Worry ifActive customer count declines or remains flat.
Why it matters: Hitting this target shows the company is growing. It proves management can drive sales.
Supportive ifQ3 revenue was at least $3.07 million. This is a 36% increase from last year.
Worry ifQ3 revenue was below $3.07 million. This means growth is not meeting goals.
Why it matters: A gross profit margin over 50% shows better operations. This supports making more money.
Supportive ifQ3 gross profit margin reported above 50%.
Worry ifQ3 gross profit margin reported below 50%.
Why it matters: Keeping this growth rate shows strong demand. It also shows the business model works well.
Supportive ifIn fiscal 2027, revenue growth is at least 38% compared to last year.
Worry ifIn fiscal 2027, revenue growth is below 38% compared to last year.
Why it matters: More cartridge sales show the company is reaching more customers. This means steady income.
Supportive ifConsumable cartridge sales grow by 35% or more each year.
Worry ifConsumable cartridge sales grow by less than 35% each year.
Why it matters: The FDA submission is key for entering the U.S. drug screening market. Approval would validate the product's market potential.
Supportive ifThe FDA 510(k) submission is filed on or before September 30, 2026.
Worry ifThe submission is delayed beyond September 2026.